Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Once Xenophobic, Big Pharma Looks Outside For Financing R&D

Executive Summary

Big pharma is increasingly taking a cue from biotech by looking externally to finance internal pipelines

You may also be interested in...



Credit Woes Hitting Even Pharma

The pharmaceutical industry may take risks with R&D, but its disciplined approach to the balance sheet has helped insulate it from the rapidly spreading global credit mess. But even pharma will not be completely shielded

Credit Woes Hitting Even Pharma

The pharmaceutical industry may take risks with R&D, but its disciplined approach to the balance sheet has helped insulate it from the rapidly spreading global credit mess. But even pharma will not be completely shielded

Pharma's Strategic Divide: Focus or Diversify

It looks like the biggest strategic gulf in the industry: focus or diversify? If the CEO thinks he can't rely on R&D to grow his way out of the industry's revenue hole, get ready to live alongside generics and OTC businesses--though he'll downplay to investors the risks of managing different businesses by stressing the commonalities with the core branded efforts and probably won't move into wholly non-pharma businesses. If he's still committed to R&D--get ready for diversification of other sorts, and some pretty clever financial tactics.

Related Content

UsernamePublicRestriction

Register

PS050183

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel